Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.76 |
| ▸ | METAP1 | P53582 | 1/20 | 0.76 |
| ▸ | MAPT | P10636 | 7/20 | 0.57 |
| ▸ | LMNA | P02545 | 6/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.57 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.57 |
| ▸ | HTT | P42858 | 3/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | MITF | O75030 | 1/20 | 0.56 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.56 |
| ▸ | CKS1B | P61024 | 1/20 | 0.56 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.56 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18419283 | 0.95 | METAP2 (0.69) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL28581571 | 0.87 | METAP2 (0.78) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL250575 | 0.87 | METAP2 (1.00) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL30309411 | 0.87 | METAP2 (1.00) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL27974930 | 0.86 | METAP2 (0.76) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL8881578 | 0.83 | KMT2A (0.54) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL15703065 | 0.81 | KMT2A (0.56) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL13977922 | 0.80 | MAPT (0.51) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL2981001 | 0.79 | TDP1 (0.56) | METAP2METAP1MAPTLMNAALDH1A1 | |
| SCHEMBL12714989 | 0.79 | METAP2 (0.48) | METAP2METAP1MAPTLMNAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116594268-A | Method for improving adhesiveness and/or developing speed of photoresist | 华中科技大学 | 2023-08-15 | — | — | CN | disclosed |
| US-10322410-B2 | Ligand for catalyst or pre-catalyst and method of forming C(SP2)-N bond | DALHOUSIE UNIVERSITY (CA) | 2019-06-18 | — | — | US | disclosed |
| US-20180141030-A1 | LIGAND FOR CATALYST OR PRE-CATALYST AND METHOD OF FORMING C(SP2)-N BOND | DALHOUSIE UNIVERSITY (CA) | 2018-05-24 | — | — | US | disclosed |
| US-20170255100-A1 | DRY FILM STRUCTURE | FUJIFILM ELECTRONIC MATERIALS U.S.A., INC. | 2017-09-07 | — | — | US | disclosed |
| WO-2016191873-A1 | LIGAND FOR CATALYST OR PRE-CATALYST AND METHOD OF FORMING C(SP2)-N BOND | DALHOUSIE UNIVERSITY (CA) | 2016-12-08 | — | — | WO | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| WO-2014066506-A2 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | CLEAVE BIOSCIENCES, INC. (US) | 2014-05-01 | — | — | WO | disclosed |
| WO-2012158435-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | ZHOU HAN-JIE (US) | 2012-11-22 | — | — | WO | disclosed |
| EP-1095035-B1 | METHOD FOR PREPARING 4-(3-PYRIDINYL)-1H-IMIDAZOLE AND THE INTERMEDIATES USED | AVENTIS PHARMA SA (FR) | 2010-03-17 | — | — | EP | disclosed |
| US-6432988-B1 | RHEUMATIC DISEASES, (OSTEO)ARTHRITIS, CACHEXIA, INFLAMMATORY BOWEL DISEASE, TOXIC SHOCK SYNDROME, SEPSIS, CROHN*S DISEASE, PSORIASIS AND GOUT TREATMENT | MERCKLE GMBH (DE) | 2002-08-13 | — | — | US | disclosed |
| US-6372733-B1 | HEXAHYDRO-5-IMINO-3-ALKYL OR ISOALKYL-1,4-THIAZEPINE HYDROCHLORIDE OR ACETIC ACID SALTS; USEFUL FOR TREATING NEURODEGENERATIVE DISORDERS, GASTROINTESTINAL DISORDERS AND INFLAMMATION | MERCK & CO., INC. | 2002-04-16 | — | — | US | disclosed |
| US-6043358-A | FOR TREATING DISSORDERS SUCH AS NEURODEGENERATIVE DISORDERS, DISORDERS OF GASTROINTESTINAL MOTILITY AND INFLAMMATION, HYPOTENSION, SEPTIC SHOCK, TOXIC SHOCK SYNDROME, HEMODIALYSIS, AUTOIMMUNE AND/OR INFLAMMATORY CONDITIONS SUCH AS SUNBURN | MERCK & CO., INC. (US) | 2000-03-28 | — | — | US | disclosed |
| US-5654297-A | CONGESTIVE HEART FAILURE, CARDIOVASCULAR DISORDERS | AMERICAN CYANAMID COMPANY (US) | 1997-08-05 | — | — | US | disclosed |
| WO-1996022294-A1 | BICYCLIC BENZAZEPINE DERIVATIVES AS VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| WO-1996022295-A1 | TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS | AMERICAN CYANAMID COMPANY (US) | 1996-07-25 | — | — | WO | disclosed |
| US-5532235-A | TO TREAT EXCESS RENAL REABSORPTION | AMERICAN CYANAMID COMPANY (US) | 1996-07-02 | — | — | US | disclosed |
| US-5475116-A | Aza bicyclo[3,1,0]hexane intermediates useful in the synthesis of quinolones | PFIZER INC. (US) | 1995-12-12 | — | — | US | disclosed |
| US-5071875-A | Nervous system, psychological disorders; sleep cycle, skin dis coloration | NORTHWESTERN UNIVERSITY (US) | 1991-12-10 | — | — | US | disclosed |
| US-3932404-A | REACTION WITH AMMONIA AND A BASIC AGENT | PECHINEY UGINE KUHLMANN (FR) | 1976-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140235548-A1 | COMPOSITIONS AND METHODS FOR JAMM PROTEIN INHIBITION | USP24, USP36, USP39 | METAP2 3619/4885METAP1 2779/4885MAPT 2894/4885 |
| US-20180141030-A1 | LIGAND FOR CATALYST OR PRE-CATALYST AND METHOD OF FORMING C(SP2)-N BOND | SP1, SOD1, AP1M1 | METAP2 2504/4885METAP1 2320/4885MAPT 4534/4885 |
| US-10322410-B2 | Ligand for catalyst or pre-catalyst and method of forming C(SP2)-N bond | SP1, SOD1, AP1M1 | METAP2 2504/4885METAP1 2320/4885MAPT 4534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.